Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LCTX vs SGMT: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

SGMT Captures Overall Composite Edge (44.6 HOLD vs 54.9 HOLD), While LCTX Leads 3–2 on Growth & Valuation Pillars

SGMT Overall Winner 6-Pillar Tally: LCTX 3 – 2 SGMT (1 Tie) Matrix Metrics: LCTX 6 – 4 SGMT

As of Nov 20, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (44.6/100 HOLD vs. 54.9/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. LCTX trades at $0.77 (30.7x Forward P/E, -280.3% operating margin) versus SGMT at $9.08 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. SGMT 44.6/100 HOLD), SGMT captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY).
  • Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1); meanwhile SGMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LCTX vs SGMT
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.77
-5.87% 1D
Market Cap $207.4M
TTM Revenue $11M
Forward P/E 30.7x
Beta / 30D Vol 1.39β · 79% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 40.0 Fund 54.0 Flow 72.0 Mom 45.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -4.6%), weak momentum, RSI 34
RSI-14: 34.1 · SMA20: $0.97 · SMA50: $0.97
SGMT NASDAQ Head-to-Head Winner
Sagimet Biosciences Inc. Series A Common Stock
Pharmaceutical Preparations
$9.08
-5.61% 1D
Market Cap $692.0M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.04β · 80% Vol
Unified Composite Score
44.6 / 100 HOLD
Tech 22.0 Fund 48.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -1.9%), weak momentum, RSI 42
RSI-14: 42.3 · SMA20: $10.14 · SMA50: $9.77

6-Pillar Scorecard Institutional Category Breakdown (LCTX 3 – 2 SGMT)

Columns: Metric · LCTX · SGMT
1. Valuation Multiples LCTX
Forward P/E 30.7x N/M
Trailing P/E 30.7x N/M
PEG Ratio 10.64x N/M
EV / Revenue 15.9x N/M
2. Growth & Scale SGMT
Revenue Growth (YoY) -61.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M N/A
Market Cap $207.4M $692.0M
3. Profitability & Quality LCTX
Gross Margin -95.0% N/A
Operating Margin -280.3% 0.0%
Net Profit Margin 16.2% 0.0%
Return on Equity (ROE) 4.3% -29.5%
4. Balance Sheet & Cash Flow LCTX
Cash Generation (TTM) -$24M -$44M
Cash Flow Margin N/A N/A
Net Cash / Leverage $35M Net Cash $109M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning SGMT
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 0.0% (<1st %ile) 489.4% (82nd %ile)
Put/Call OI Skew N/A 0.10x (Call-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LCTX (6) vs SGMT (4)
Institutional Metric LCTX SGMT Criterion Row Edge
Market Capitalization
Scale
$207.4M $692.0M Larger Scale SGMT
Trailing P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Forward P/E Ratio
Valuation
30.7x N/M Lower Multiple LCTX
Revenue Growth (YoY)
Growth
-61.0% +0.0% Higher Growth SGMT
Operating Margin (TTM)
Profitability
-280.3% 0.0% Higher Margin SGMT
Net Profit Margin
Profitability
16.2% 0.0% Higher Margin LCTX
Return on Equity (ROE)
Capital Efficiency
4.3% -29.5% Higher ROE LCTX
52-Week Range Position
Momentum
0% ($1–$2) 66% ($4–$11) Stronger Trend SGMT
Beta / 30D Volatility
Risk Regime
1.39β · 79% Vol 2.04β · 80% Vol Lower Realized Risk LCTX
Unified Institutional Score
Composite Signal
54.9 / 100 (HOLD) 44.6 / 100 (HOLD) Higher Composite LCTX
Trailing 12M Revenue (USD)
Operating Scale
$11M N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-95.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
10.64x PEG · 15.9x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$24M ($35M Net Cash) -$44M ($109M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon SGMT +12.89 pp
LCTX: -21.63% · SGMT: -8.74%
3M Horizon SGMT +18.11 pp
LCTX: -29.18% · SGMT: -11.07%
6M Horizon SGMT +68.69 pp
LCTX: -40.62% · SGMT: +28.07%
1Y Horizon SGMT +70.53 pp
LCTX: -54.86% · SGMT: +15.67%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period LCTX Revenue SGMT Revenue LCTX Op. Margin SGMT Op. Margin Margin Leader
FY2018 $0M N/A -837.9% N/A LCTX
FY2019 $0M N/A -1106.0% N/A LCTX
FY2020 $0M N/A -1448.4% N/A LCTX
FY2021 $0M N/A -1133.6% N/A LCTX
FY2022 $10M N/A -153.2% N/A LCTX
FY2023 $10M $0M -276.5% -1537.0% LCTX
FY2024 $10M N/A -226.1% N/A LCTX
FY2025 $10M N/A -251.6% N/A LCTX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LCTX BREAKDOWN
7d in phase · OBV DISTRIBUTION
Current IV 0.0%
IV Percentile <1st %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact LCTX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
SGMT CONSOLIDATION
144d in phase · OBV NEUTRAL
Current IV 489.4%
IV Percentile 82nd %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact SGMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LCTX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $207.4M market capitalization and -280.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
SGMT Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $692.0M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ LCTX vs SGMT Key Questions & Quantitative Answers

As of Nov 20, 2026, Sagimet Biosciences Inc. Series A (SGMT) captures the overall head-to-head institutional edge over Lineage Cell Therapeutics, Inc. (LCTX) on higher Unified Composite conviction (44.6/100 HOLD vs. 54.9/100 HOLD) after splitting the core matrix 4–6 (led by Growth & Scale, Options & Positioning), while LCTX wins 3–2 across the 6-pillar growth and valuation breakdown. LCTX trades at $0.77 (30.7x Forward P/E, -280.3% operating margin) versus SGMT at $9.08 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While LCTX currently prints a higher short-term Unified Composite Score (54.9/100 HOLD vs. SGMT 44.6/100 HOLD), SGMT captures the overall institutional head-to-head verdict (4–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -280.3% operating margin) and revenue trajectory (+0.0% vs. -61.0% YoY). Technical & Structure Timing Caution: LCTX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.1); meanwhile SGMT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 42.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

SGMT leads the Growth & Scale pillar: LCTX posts -61.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (-95.0% gross margin, -280.3% operating margin), compared with SGMT at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), LCTX cumulative revenue shifted +0.0% while SGMT shifted N/A. In operating R&D and SG&A reinvestment, LCTX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for SGMT.

LCTX screens cheaper on headline valuation multiples. LCTX trades at 30.7x Forward P/E, 30.7x Trailing P/E, 10.64x PEG, and 15.9x EV/Revenue (unreported FCF margin), whereas SGMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LCTX (4.3% ROE) versus SGMT (-29.5% ROE) capital efficiency.

In options market volatility and institutional positioning, LCTX carries 0.0% implied volatility (<1st %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.39β · 79% Vol realized risk). By comparison, SGMT carries 489.4% implied volatility (82nd %ile, Extreme (>80th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (2.04β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.